NeuralTier 3 β Animal + early human data
Dihexa
PNB-0408 Β· N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
Hepatocyte growth factor (HGF) potentiator that dramatically enhances synaptogenesis and cognitive performance in animal models. Very early human data β considered highly experimental.
π Oral / Transdermalπ§ Sealed: room temperature or refrigerate; reconstituted: refrigerate, use within 14 days
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Allosteric potentiator of HGF-MET receptor signalling, dramatically upregulating synaptogenesis. Shown to be ~10 million-fold more potent than BDNF in some in vitro models.
Clinical Applications
- βCognitive enhancement (experimental)
- βAlzheimer's disease research
- βNeurodegeneration prevention
- βTraumatic brain injury (investigational)
Dosing Protocol
Recommended Dosing
Oral or transdermal. Doses used in research: 1β3 mg/day. Extremely potent β start very low. No established clinical protocols. Duration unknown.Safety & Contraindications
Possible Side Effects
- β Unknown β no human clinical trials
- β Potential pro-oncogenic (MET signalling β monitor)
- β Unknown long-term effects
Contraindications
- βAny malignancy history (MET pathway implicated in cancer)
- βPregnancy
- βAll autoimmune liver disease
Combinations & Synergies
π Semaxsynergistic BDNF/neurotrophin support
π Selankcognitive enhancement with anxiolytic balance